National
Right-wing media watchdog project launched
Equality Matters created by gay ex-conservative David Brock
Former Clinton administration official Richard Socarides will head the newly created Equality Matters. (Photo courtesy Equality Matters)
Gay former conservative strategist and author David Brock, who changed sides in 2002 to become a champion of LGBT equality and progressive causes, announced the founding this week of a new initiative aimed at exposing “right-wing bigotry and homophobia wherever we find it.”
Brock said the new entity, Equality Matters, would be an arm of the progressive-leaning media watchdog group he founded in 2004 called Media Matters.
A statement released Monday says New York gay attorney and former Clinton administration official Richard Socarides would serve as president of Equality Matters. Lesbian journalist and Washington correspondent for The Advocate, Kerry Eleveld, was named editor of the project’s website, EqualityMatters.org, which organizers say will provide “news, opinion, and messaging” on LGBT-related issues in the media.
“Despite huge progress in gay rights in recent years, exemplified by the historic vote [on Dec. 18] finally striking down the ban on gay men and women from serving in the military, we are now living through a period of ferocious fundamentalism in the Republican Party and the conservative movement,” Brock said.
“Traditional conservatives and the Tea Party movement are united only in their contempt for equal rights for all Americans and a desire to return America to a 19th century idyll,” he said. “Equality Matters will not allow these latter-day ‘clerics’ to gain serious recognition by the media nor influence the policies that affect the lives of every American.”
A source familiar with Media Matters said the group and an affiliated entity, Media Matters Action network, raised about $23 million in 2010 in cash contributions and “long term commitments for 2011 and 2012.”
The New York Times reported that much of Media Matters’ funding comes from large contributions by wealthy liberal donors, including gay philanthropists.
The Blade source, who spoke on condition of not being identified, said the two entities yielded between $13 million and $14 in revenue this year. The 2010 figure disclosed by the source represents a significant boost in Media Matters’ revenue of $6.7 million in 2009 and $8.09 million raised in 2008, according to reports the group filed with the IRS in 2008 and 2009.
Socarides told the Blade Tuesday that Equality Matters would not have a separate budget and instead would operate under the Media Matters budget. He said Equality Matters, which would be based in the same offices as Media Matters at 455 Massachusetts Ave., N.W., would operate initially with a six-person staff, including him and Eleveld.
“We will draw on the Media Matters staff extensively,” he said. “And there are just under 100 people who work there. So we’ll have six people dedicated to just this and then parts of 95 others.”
According to Socarides, Equality Matters will not be involved in direct lobbying and won’t make campaign contributions – unlike existing LGBT groups like the Human Rights Campaign and the National Gay & Lesbian Task Force.
“Much like Media Matters already does on a broad range of issues, we will do news and information media monitoring,” he said. “And we’ll be a rapid response to any homophobic misinformation in the media or in political discourse. So part of our mission is to respond rapidly with smart and accurate information when the right wing – be it in media or politics – puts out misinformation.”
At least two activists involved with national LGBT groups said the launching of Equality Matters would likely trigger speculation among LGBT movement insiders about whether Brock and Socarides were seeking to step into the realm of other national LGBT groups that came under some criticism in the past year.
Expectations were high in January 2009 for significant progress on LGBT-related legislation as President Obama entered the White House and Democrats were in control of Congress, the two activists said. Although Congress passed an important hate crimes law last year with protections for LGBT people and last week repealed “Don’t Ask, Don’t Tell,” all other important bills remain stalled in committee. Among them is the Employment Non-Discrimination Act, or ENDA, which calls for banning employment discrimination based on sexual orientation and gender identity.
“The feeling among some of us is the established groups could have done more and could have put more pressure on the Democrats to do more,” said one of the activists.
But others, including gay U.S. Rep. Barney Frank (D-Mass.), considered one of the leading advocates for LGBT rights in Congress, have said there were not enough LGBT-supportive votes in Congress to advance the other bills. Frank has said it is up to LGBT advocates to do the lobbying and advocacy work in the sections of the country, especially the so-called “red states,” where members of Congress oppose LGBT equality and won’t vote for pro-gay bills.
Socarides said he sees Equality Matters as a new force that will work with the existing groups, including the Human Rights Campaign and Gay & Lesbian Alliance Against Defamation (GLAAD), which also specializes in media-related initiatives.
One gay activist, who spoke on condition of anonymity, questioned whether Equality Matters would be replicating the work of existing groups.
“Media Matters is fantastic at pushing back at conservative disinformation, and if they’re ramping up that function in the gay space, God bless,” the activist said. “But if they’re doing policy advocacy, plenty of people with vastly more substantive experience than Socarides are doing that pretty well, as the passage of DADT suggests. It’s not clear this isn’t a completely redundant vanity project, but I guess we’ll see.”
GLAAD, which has a budget of $7.95 million and a 48-member staff located in New York and Los Angeles, focuses on the positive portrayal of LGBT people in the media and in entertainment, according to its president, Jarrett Barrios.
“GLAAD fights defamation in the media from major outlets to small markets around the country,” Barrios said. “Some of GLAAD’s most visible work is in Hollywood, but much of our work is with journalists and news organizations to ensure accurate and responsible coverage of LGBT peoples’ lives and the issues that affect them.”
He said that unlike Equality Matters’ stated objective, GLAAD steers clear of addressing specific political and policy-making issues.
“I think our effort will be complimentary rather than overlapping with GLAAD,” said Socarides. “And in fact one of our core missions at Media Matters and at Equality Matters is to help other progressive and LGBT rights organizations fulfill their own missions.”
Now that “Don’t Ask, Don’t Tell” has been addressed legislatively, Socarides said Equality Matters plans to devote much of its resources to promoting same-sex marriage equality, both on the national and state level. He said the group would jump into the media fray as ballot measures seeking to ban same-sex marriage surface in the states.
He said Equality Matters would also push to advance legislation stalled in Congress to overturn the Defense of Marriage Act, which defines marriage under federal law as a union only between a man and a woman and bars all federal programs – including Social Security benefits – for same-sex married couples.
“Despite our best efforts over the years to stiffen the spines of progressives in the face of unrelenting smears from the Republican attack machine, fearful progressives continue to cede the political field to right-wingers who are waging war against core American values,” Brock said in a statement. “We need to do more. Our new communication war room for gay equality, Equality Matters, will expose right-wing bigotry and homophobia wherever we find it, show that the real political vulnerability on these issues belongs to the GOP, provide desperately needed ballast in the media, and trigger progressive passion – so that our political leaders act on their convictions and fight for them,” he said.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
